Genome Engineering of Hybridomas to Generate Stable Cell Lines for Antibody Expression

Parola, Cristina; Mason, Derek M; Zingg, Andreas; Neumeier, Daniel

doi:10.1007/978-1-4939-8730-6_7

Cited by 5 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Beyond editing the human genome, gene editing approaches can be used to target other organisms and aid in the development of therapeutics. For example, editing of viral genomes has been shown to aid in the process of vaccine development [70], and editing of antibody-producing organisms can aid in production and development of antibody-based therapies [71]- [73].…”

Section: Therapeutic Genome Editingmentioning

confidence: 99%

Therapeutic gene editing is here, can regulations keep up?

Kannan

Najjar

2020

MIT Science Policy Review

View full text Add to dashboard Cite

Genome editing and the technologies that enable it have sparked public discussions as investments in research and development continue to soar. Available gene editing modalities are enabling far-reaching applications beyond heritable genome modifications, ranging from novel therapeutics and cancer immunotherapies to engineered crops and livestock. However, many challenges, both practical and ethical, still exist before genome editing technologies can be implemented. Existing legal frameworks, both national and international, are racing to keep pace with the development of gene editing technologies. Updating regulations on gene editing can help provide a framework under which scientists and the public operate. Shaping and implementing proper regulations will require engagement from all impacted stakeholders. Here, we present a comprehensive review of the current scientific and regulatory landscape of this field of gene editing in order to stimulate necessary conversations regarding future regulations in the broader community

show abstract

Section: Therapeutic Genome Editingmentioning

confidence: 99%

Therapeutic gene editing is here, can regulations keep up?

Kannan

Najjar

2020

MIT Science Policy Review

View full text Add to dashboard Cite

show abstract

“…Mammalian cell lines have been adapted to suspension culture, as they support higher cell densities and mAb titers in the absence of serum from the culture media, for large scale fed-batches, perfusion systems, or continuous culture systems. Further to this, cell lines are continually being engineered for enhanced metabolic functions, introducing glycosylation pathways, superior secretion, and resistance to apoptosis for prolonged survival, in efforts to generate super-producer cell lines that can sustain a continuous culture [62,63,64,65,66,67,68].…”

Section: Mab Discovery and Manufacture Technologiesmentioning

confidence: 99%

Current Advancements in Addressing Key Challenges of Therapeutic Antibody Design, Manufacture, and Formulation

et al. 2019

View full text Add to dashboard Cite

Therapeutic antibody technology heavily dominates the biologics market and continues to present as a significant industrial interest in developing novel and improved antibody treatment strategies. Many noteworthy advancements in the last decades have propelled the success of antibody development; however, there are still opportunities for improvement. In considering such interest to develop antibody therapies, this review summarizes the array of challenges and considerations faced in the design, manufacture, and formulation of therapeutic antibodies, such as stability, bioavailability and immunological engagement. We discuss the advancement of technologies that address these challenges, highlighting key antibody engineered formats that have been adapted. Furthermore, we examine the implication of novel formulation technologies such as nanocarrier delivery systems for the potential to formulate for pulmonary delivery. Finally, we comprehensively discuss developments in computational approaches for the strategic design of antibodies with modulated functions.

show abstract

“…Hybridomas represent an ideal eukaryotic cell system in which to attempt the CRISPR/Cas9 strategy for protein expression. Recent studies successfully demonstrated the use of the CRISPR/Cas9 system combined with Homology Directed Repair (HDR) to edit the genome of hybridomas (Pogson et al, 2016;Parola et al, 2018Parola et al, , 2019. The aim of such studies is usually the modification of mAbs; for example, to obtain antibodies in a specific format, with the possibility of inserting tags or mutations, or to knock out the antibody constant region in order to express an antibody fragment instead of the whole immunoglobulin (Cheong et al, 2016;Khoshnejad et al, 2018;van der Schoot et al, 2019).…”

Section: Introductionmentioning

confidence: 99%